[
    "{\"step_by_step_thinking\": \"Based on the provided documents, there is evidence to suggest that the timing of initial surfactant treatment does make a difference in rates of chronic lung disease or mortality in premature infants. Document [0] states that early surfactant administration is associated with shorter duration of ventilation but does not significantly protect against chronic lung disease/mortality. However, Document [2] shows that early selective surfactant administration leads to a decreased risk of neonatal mortality and chronic lung disease compared to delaying treatment. Additionally, Document [26] states that early surfactant replacement therapy with extubation to nasal CPAP is associated with a reduced need for mechanical ventilation and increased utilization of exogenous surfactant therapy. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]